The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment

Completed · Phase 4 · Has a placebo group

Conditions studied: Mild Cognitive Impairment, Depression

In brief

The purpose of this study is to determine whether Cymbalta (duloxetine) is effective to improve cognition in individuals with Mild Cognitive Impairment.

Key facts

Study ID

NCT02590874

Run by

University of North Texas Health Science Center

People needed

19

Starts

2016-01-01

Expected to finish

2018-10-01

Last updated by the study team

2018-10-11

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female, age 50 and up.
• Female participants must be post-menopausal for at least two consecutive years.
• Health and Aging Brain Study participant, who provided consent for re-contact
• Diagnosis of MCI (by Health and Aging Brain Study Consensus Review).
• Has an elevated DepE score (2 or more). This is calculated by summing scores for five items (Items 14, 16, 17,25 \&26) on the Geriatric Depression Scale.

You may not qualify if…

• Inability to provide informed consent by self or by proxy.
• Pregnant or breast feeding women
• Uncontrolled narrow angle glaucoma
• Known hypersensitivity to duloxetine.
• Participation in a Clinical Trial in the last three months.
• Other psychiatric disorder like bipolar disorder, schizophrenia, or dementia.
• Use of antidepressants, anti-psychotics, and mood stabilizers.
• History of stroke.

Where it is running

• University of North Texas Health Science Center — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.